|
Orthologous residues
|
|
LDH‑A (human): Y10‑p, LDH‑A iso3 (human): Y39‑p, LDH‑A (mouse): V10‑p, LDH‑A (rat): V10‑p, LDH‑A (chicken): H9‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry (in vitro), phospho-antibody, western blotting
|
|
Disease tissue studied:
breast cancer, leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroid leukemia, lung cancer, non-small cell lung cancer, prostate cancer
|
|
Relevant cell lines - cell types - tissues:
212LN, 22Rv1 (prostate cell), 686LN, EOL-1 (myeloid), HEL (erythroid), K562 (erythroid), KG-1a, MDA-MB231 (breast cell), Molm 14 (myeloid), NCI-H1299 (pulmonary), NCI-H157 (pulmonary), NCI-H358 (pulmonary), PC3 (prostate cell), Tu212, Tu686
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
TKI258
|
|
|
|
decrease
|
|
|
AG490
|
|
|
|
decrease
|
|
|
imatinib
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced, molecular association, regulation
|
|
Effect of modification (process):
carcinogenesis, induced, cell growth, induced
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
LDH-A (human)
|
|
Induces
|
|
|
affinity chromatography
|
|
|
|